Epigenetic editing: the next generation of genetic medicine
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
List view / Grid view
Articles
Exploring alternatives to animal testing in drug discovery
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
Targeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
The promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
More than just a microscope: how advanced imaging modalities can take your pharmaceutical research to the next level
When you think of microscopy for drug discovery, you may picture images of fixed cells or histologically stained sections of biopsies, collected long after a drug has taken effect. Instead, imagine watching drug responses in real time in whole living animals, visualising drug delivery vehicles at nanoscale and removing the…
Advancing directed protein evolution technology
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
Key considerations before commencing cell line development
Cell line development (CLD) is a critical, early step when entering the development phase of a biotherapeutic. Access to specialist skills and experience, either in-house or remotely, and to multiple technologies and equipment can prove invaluable for the timely and successful completion of this stage. Here, Dr Alison Porter addresses…
The power of single-cell technologies
Drug Target Review’s Taylor Mixides interviews Cellarity's CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies.
Antibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…
A 3D tool for measuring intracellular lipid droplets
Tomographic phase microscopy in flow cytometry showcases its ability to accurately measure intracellular lipid droplets.
T cells’ vital role in boosting immune responses
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
Next-generation CAR T cells
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
Advancing gene editing to redefine therapies across genetic disease
In the unmet need for effective treatments to alleviate suffering and prevent premature death across the spectrum of genetic diseases, Brent Warner, Poseida Therapeutics, shares that the ability to edit DNA holds hope for patients currently experiencing incurable genetic diseases and has spurred ongoing efforts to develop and improve gene…
The evolution and promise of gene therapies
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
Women in STEM with Dr Jo Brewer
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been…
